VC Briefs: Gemini’s $42M for Dry AMD & Mission Bio’s $10M for Single-Cell Analysis

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.